Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Open accessThe DOI matches its Crossref record; 486 of the 486 references it cites were found in a registry or an index.
Abstract
Cancers are highly complex diseases that are characterized by not only the overgrowth of malignant cells but also an altered immune response. The inhibition and reprogramming of the immune system play critical roles in tumor initiation and progression. Immunotherapy aims to reactivate antitumor immune cells and overcome the immune escape mechanisms of tumors. Represented by immune checkpoint blockade and adoptive cell transfer, tumor immunotherapy has seen tremendous success in the clinic, with the capability to induce long-term regression of some tumors that are refractory to all other treatments. Among them, immune checkpoint blocking therapy, represented by PD-1/PD-L1 inhibitors (nivolumab) and CTLA-4 inhibitors (ipilimumab), has shown encouraging therapeutic effects in the treatment of various malignant tumors, such as non-small cell lung cancer (NSCLC) and melanoma. In addition, with the advent of CAR-T, CAR-M and other novel immunotherapy methods, immunotherapy has entered a new era. At present, evidence indicates that the combination of multiple immunotherapy methods may be one way to improve the therapeutic effect. However, the overall clinical response rate of tumor immunotherapy still needs improvement, which warrants the development of novel therapeutic designs as well as the discovery of biomarkers that can guide the prescription of these agents. Learning from the past success and failure of both clinical and basic research is critical for the rational design of studies in the future. In this article, we describe the efforts to manipulate the immune system against cancer and discuss different targets and cell types that can be exploited to promote the antitumor immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Liu, Y., Liang, X., Yin, X., Lv, J., Tang, K., Ma, J., Ji, T., Zhang, H., Dong, W., Jin, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15207 · Cited by 212
RetractedRETRACTED: CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
Marofi, F., Al-Awad, A. S., Rahman, H. S., Markov, A. A., Abdelbasset, W. K., Enina, Y. I., Mahmoodi, M., Hassanzadeh, A., Yazdanifar, M., Chartrand, M. S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.673276 · Cited by 101
RetractedWang, Y., Zhong, K., Ke, J., Chen, X., Chen, Y., Shu, W., Chen, C., Hu, S., Sun, X., Huang, H., et al. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.02.117 · Cited by 23
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“In 1997, Allison’s team suggested that both inducing T-cell costimulatory signals and reducing inhibitory signals can be potential approaches for cancer immunotherapy.(33) In 2011, ipilimumab, the first antibody targeting CTLA-4, was approved for melanoma treatment and became the first immune checkpoint (IC) inhibitor.”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 2×
“In 1999, the research group of Lieping Chen at the Mayo Clinic discovered a molecule named B7-H1,(38) which was later found to be expressed on tumor tissues such as melanoma and lung cancer and can promote the apoptosis of tumor-specific T cells, making them unable to attack cancer cells.(39) In 2000, B7-H1 was identi…”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“In 2002, the Michel Sadelain group incorporated the costimulatory domain into the CAR construct.(50) The resulting “second-generation” CARs have seen extraordinary clinical responses against malignancies of the B-cell lineages, including B-cell chronic lymphocytic leukemia (B-CLL) and B-cell acute lymphocytic leukemia…”
BackgroundIshida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · cited 1×
“The first signal is an antigenspecific signal, which involves the specific binding of the T-cell surface receptor (TCR) to the antigenic peptide-major histocompatibility complex (MHC).(11,12) The second signal is mediated by the communication of T cells with costimulatory molecules (CMs) on the surface of antigen-pres…”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 1×
“In 1996, James Allison found that blocking CTLA-4 caused tumor regression in mice.(148) In subsequent human studies, the CTLA-4 antibody ipilimumab was the first-in-class ICB agent to be tested in clinical studies.”
BackgroundPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · cited 1×
“The concept that CTLA-4 is a positive immune regulator was also shown in other studies(22) but was later challenged by the teams of James Allison and Jeffery Bluestone, who independently discovered that blocking CTLA-4 enhanced the T-cell immune response.(27,28) Consistently, disrupting the CTLA-4 gene was lethal in m…”
ResultOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · cited 1×
“However, it remains challenging to validate the “quality” of neoantigens, which refers to their capability to elicit immune recognition and activation.(410) Currently, neoantigens are mostly used to support other biomarkers.”
BackgroundLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 3×
“The first signal is an antigenspecific signal, which involves the specific binding of the T-cell surface receptor (TCR) to the antigenic peptide-major histocompatibility complex (MHC).11,12 The second signal is mediated by the communication of T cells with costimulatory molecules (CMs) on the surface of antigen-presen…”
BackgroundNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“More than 20 years ago, the research group of Tasuku Honjo at Kyoto University discovered programmed cell death protein 1 (PD-1).(36) PD-1 knockout led to autoimmune disease and abnormally activated immune cells in mice,(37) suggesting its immune-suppressive role.”
ResultImmune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · cited 1×
“The clinical efficacy of PD-1/L1 blocking antibodies was first observed against tumors with high PD-L1 expression, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC).(42,106,107) The PD-1 blocking antibody nivolumab (Opdivo) was approved in 2015 for advanced squamous cell lung cance…”
BackgroundCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation
Italiani, P., & Boraschi, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00514 · Cited by 2,067 · cited 1×
“Macrophages are also highly plastic cells that can switch from one phenotype to another depending on microenvironmental stimuli and signals.(454) The activation state of macrophages is usually divided into two categories: M1-type macrophages and M2-type macrophages (Fig.”
BackgroundThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109970 · Cited by 1,883
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts
Weiden, P. L., Flournoy, N., Thomas, E. D., Prentice, R., Fefer, A., Buckner, C. D., & Storb, R. (1979) · New England Journal of Medicine · doi:10.1056/nejm197905103001902 · Cited by 1,510
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399 · cited 1×
“In 2011, ipilimumab, the first antibody targeting CTLA-4, was approved for melanoma treatment and became the first immune checkpoint (IC) inhibitor.(34,35) More than 20 years ago, the research group of Tasuku Honjo at Kyoto University discovered programmed cell death protein 1 (PD-1).”
BackgroundCD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1456-0 · Cited by 1,385
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310 · cited 5×
“It is mainly expressed in lymphoid organs and bone marrow cells, and its structure is similar to that of PD-L1.”
BackgroundInfluentialDistinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 3×
“The combinational therapy of CTLA-4 and PD-1 ICBs indeed resulted in superior clinical responses but led to more significant adverse effects than monotherapy.(153)”
BackgroundIL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Yanagi, Y., Yoshikai, Y., Leggett, K., Clark, S. P., Aleksander, I., & Mak, T. W. (1984) · Nature · doi:10.1038/308145a0 · Cited by 1,264
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02229 · Cited by 1,117
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors
Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.012 · Cited by 1,000
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960 · cited 1×
“Unfortunately, no objective response was observed, but seven patients had stable disease for more than 16 weeks.(502) In another phase I/II clinical study, epacadostat was combined with pembrolizumab, and a total of 54 patients with solid tumors were included.”
BackgroundMechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Targeting tumor-associated macrophages in cancer
Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Formenti, S. C., Rudqvist, N.-P., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Friedman, K., Ferrari de Andrade, L., Wucherpfennig, K. W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0232-2 · Cited by 928 · cited 1×
“Although it was later found that Treg depletion is not the main mechanism of the clinical antitumor efficacy of ipilimumab,(144) these results suggest that the CTLA-4 antibody may also inhibit Treg cells in the TME under certain circumstances and contribute to immune activation.(136,151,152) Although both are represen…”
BackgroundDecade-long leukaemia remissions with persistence of CD4+ CAR T cells
Melenhorst, J. J., Chen, G. M., Wang, M., Porter, D. L., Chen, C., Collins, M. A., Gao, P., Bandyopadhyay, S., Sun, H., Zhao, Z., et al. (2022) · Nature · doi:10.1038/s41586-021-04390-6 · Cited by 923
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 896
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 880
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Wang, J., Sanmamed, M. F., Datar, I., Su, T. T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.010 · Cited by 871
Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis
Chen, S., Sanjana, N. E., Zheng, K., Shalem, O., Lee, K., Shi, X., Scott, D. A., Song, J., Pan, J. Q., Weissleder, R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.038 · Cited by 862
Tim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 824
Chauvin, J.-M., & Zarour, H. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000957 · Cited by 794
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Chauvin, J.-M., Pagliano, O., Fourcade, J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 784
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Vitaly, K., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 783
Oncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774
Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., Vynnychenko, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30436-8 · Cited by 751
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
Macrophage-Based Approaches for Cancer Immunotherapy
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2990 · Cited by 698
Goldman, J. W., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30539-8 · Cited by 688
MDSC: Markers, development, states, and unaddressed complexity
Hegde, S., Leader, A. M., & Merad, M. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.004 · Cited by 669
(2011) · Hepatogastroenterology · doi:10.5754/hge11387 · Cited by 660
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Hamieh, M., Dobrin, A., Cabriolu, A., van der Stegen, S. J. C., Giavridis, T., Mansilla-Soto, J., Eyquem, J., Zhao, Z., Whitlock, B. M., Miele, M. M., et al. (2019) · Nature · doi:10.1038/s41586-019-1054-1 · Cited by 654
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V. P., Hellmann, M. D., Solovyov, A., Rizvi, N. A., Merghoub, T., Levine, A. J., Chan, T. A., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 646
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Powles, T., Assaf, Z. J., Davarpanah, N., Banchereau, R., Szabados, B. E., Yuen, K. C., Grivas, P., Hussain, M., Oudard, S., Gschwend, J. E., et al. (2021) · Nature · doi:10.1038/s41586-021-03642-9 · Cited by 646
Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.06.015 · Cited by 631
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Daniel, B., Klysz, D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 607
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01436-0 · Cited by 606
Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Linsley, P. S., Greene, J. L., Tan, P., Bradshaw, J., Ledbetter, J. A., Anasetti, C., & Damle, N. K. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1595 · Cited by 581
Tuning the Antigen Density Requirement for CAR T-cell Activity
Majzner, R. G., Rietberg, S. P., Sotillo, E., Dong, R., Vachharajani, V. T., Labanieh, L., Myklebust, J. H., Kadapakkam, M., Weber, E. W., Tousley, A. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0945 · Cited by 573
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
TIGIT as an emerging immune checkpoint
Harjunpää, H., & Guillerey, C. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13407 · Cited by 552
Wolchok, J. D., Chiarion‐Sileni, V., Gonzalez, R. C., Grob, J., Rutkowski, P. L., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J. D., Dummer, R., et al. (2022) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-213514 · Cited by 550
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
Feucht, J., Sun, J., Eyquem, J., Ho, Y.-J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., & Sadelain, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0290-5 · Cited by 547
CD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544 · cited 1×
“This approach reduces the number of TAMs, which can also be associated with the repolarization of TAMs toward the M1 phenotype.(458) However, the leading CSF1R inhibitor, cabiralizumab from Five Prime Therapeutics, did not show promising clinical responses in a series of clinical trials,(459) indicating that the poten…”
BackgroundInhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Andrews, L. P., Yano, H., & Vignali, D. A. A. (2019) · Nature Immunology · doi:10.1038/s41590-019-0512-0 · Cited by 543
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody.
Allison, J. P., McIntyre, B. W., & Bloch, D. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.5.2293 · Cited by 541
Clinical Challenges of Immune Checkpoint Inhibitors
de Miguel, M., & Calvo, E. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.004 · Cited by 540
Goldberg, S. B., Schalper, K. A., Gettinger, S. N., Mahajan, A., Herbst, R. S., Chiang, A. C., Lilenbaum, R., Wilson, F. H., Omay, S. B., Yu, J. B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30111-x · Cited by 539
Lu, Y., Xue, J., Deng, T., Zhou, X., Yu, K., Deng, L., Huang, M., Yi, X., Liang, M., Wang, Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0840-5 · Cited by 539
Regulatory mechanisms in T cell receptor signalling
Gaud, G., Lesourne, R., & Love, P. E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0020-8 · Cited by 532
Motzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., Mu, X. J., Ching, K. A., Uemura, M., Pal, S. K., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1044-8 · Cited by 518
TAM Receptor Signaling in Immune Homeostasis
Rothlin, C. V., Carrera-Silva, E. A., Bosurgi, L., & Ghosh, S. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112103 · Cited by 510
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Fu, W., Lei, C., Liu, S., Cui, Y., Wang, C., Qian, K., Li, T., Shen, Y., Fan, X., Lin, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12321-3 · Cited by 496
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Schubert, M.-L., Schmitt, M., Wang, L., Ramos, C. A., Jordan, K., Müller-Tidow, C., & Dreger, P. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.478 · Cited by 491
T cell responses to cytomegalovirus
Klenerman, P., & Oxenius, A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.38 · Cited by 483
Immune Checkpoint Inhibitors: Basics and Challenges
Li, B., Chan, H. L., & Chen, P. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170804143706 · Cited by 480
CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Miliotou, A. N., & Papadopoulou, L. C. (2018) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180418095526 · Cited by 480
Parker, K. R., Migliorini, D., Perkey, E., Yost, K. E., Bhaduri, A., Bagga, P., Haris, M., Wilson, N. E., Liu, F., Gabunia, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.022 · Cited by 455
Alizadeh, D., Wong, R. A., Yang, X., Wang, D., Pecoraro, J. R., Kuo, C.-F., Aguilar, B., Qi, Y., Ann, D. K., Starr, R., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0466 · Cited by 453
Self-citationLifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Sarnaik, A. A., Hamid, O., Khushalani, N. I., Lewis, K. D., Medina, T., Kluger, H. M., Thomas, S. S., Domingo-Musibay, E., Pavlick, A. C., Whitman, E. D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00612 · Cited by 451
Self-citationTargeting the IDO1 pathway in cancer: from bench to bedside
Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 447
The Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 446
Wang, F., Zhao, Q., Wang, Y.-N., Jin, Y., He, M.-M., Liu, Z.-X., & Xu, R.-H. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2963 · Cited by 436
TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy
Dougall, W. C., Kurtulus, S., Smyth, M. J., & Anderson, A. C. (2017) · Immunological Reviews · doi:10.1111/imr.12518 · Cited by 435
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Xu-Monette, Z. Y., Zhou, J., & Young, K. H. (2018) · Blood · doi:10.1182/blood-2017-07-740993 · Cited by 433
Harper, K., Balzano, C., Rouvier, E., Mattéi, M. G., Luciani, M. F., & Golstein, P. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.3.1037 · Cited by 432
Creelan, B. C., Wang, C., Teer, J. K., Toloza, E. M., Yao, J., Kim, S., Landin, A. M., Mullinax, J. E., Saller, J. J., Saltos, A. N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01462-y · Cited by 428
Gholamin, S., Mitra, S. S., Feroze, A. H., Liu, J., Kahn, S. A., Zhang, M., Esparza, R., Richard, C., Ramaswamy, V., Remke, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2968 · Cited by 426
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Bielamowicz, K., Fousek, K., Byrd, T. T., Samaha, H., Mukherjee, M., Aware, N., Wu, M.-F., Orange, J. S., Sumazin, P., Man, T.-K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox182 · Cited by 425
Rodríguez-Abreu, D., Powell, S. F., Hochmair, M. J., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., De Angelis, F., Dómine, M., Cheng, S. Y., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.008 · Cited by 415
Treg and CTLA-4: Two intertwining pathways to immune tolerance
Walker, L. S. K. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.006 · Cited by 411
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Gao, S., Li, N., Gao, S., Xue, Q., Ying, J., Wang, S., Tao, X., Zhao, J., Mao, Y., Wang, B., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.017 · Cited by 401 · cited 1×
“Another two new PD-L1 antibodies, durvalumab (Imfinzi) and avelumab (Bavencio), were approved in 2017.(122,123) Furthermore, sindilizumab, a PD-1 antibody developed by Innovent Biologics in China, also achieved good results after two cycles of neoadjuvant administration,(124) representing another candidate to target t…”
BackgroundSelf-citationImmune checkpoint therapy in liver cancer
Xu, F., Jin, T., Zhu, Y., & Dai, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0777-4 · Cited by 397
New development in CAR-T cell therapy
Wang, Z., Wu, Z., Liu, Y., & Han, W. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0423-1 · Cited by 396
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B., & Allison, J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8099 · Cited by 394
Tim-3 finds its place in the cancer immunotherapy landscape
Acharya, N., Sabatos-Peyton, C., & Anderson, A. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000911 · Cited by 394
Sahin, I. H., Akce, M., Alese, O., Shaib, W., Lesinski, G. B., El-Rayes, B., & Wu, C. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0599-y · Cited by 393
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Zappasodi, R., Serganova, I., Cohen, I. J., Maeda, M., Shindo, M., Senbabaoglu, Y., Watson, M. J., Leftin, A., Maniyar, R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 393
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382 · cited 1×
“Ipilimumab performed well and successfully inhibited disease progression in patients with refractory metastatic melanoma, which was a milestone of cancer immunotherapy.(149) Intriguingly, CTLA-4 was particularly highly expressed on the surface of Treg cells infiltrated by melanoma, lung cancer and kidney cancer.”
BackgroundImmune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J. M., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84940 · Cited by 380
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A. A., Schenk, A. D., Miller, H. E., Guleria, I., Barth, R. J., Huang, Y. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420370112 · Cited by 374
TIM-3 restrains anti-tumour immunity by regulating inflammasome activation
Dixon, K. O., Tabaka, M., Schramm, M. A., Xiao, S., Tang, R., Dionne, D., Anderson, A. C., Rozenblatt-Rosen, O., Regev, A., & Kuchroo, V. K. (2021) · Nature · doi:10.1038/s41586-021-03626-9 · Cited by 372
Banta, K. L., Xu, X., Chitre, A. S., Au-Yeung, A., Takahashi, C., O’Gorman, W. E., Wu, T. D., Mittman, S., Cubas, R., Comps-Agrar, L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.02.005 · Cited by 370
Tumor-Associated Macrophages: Implications in Cancer Immunotherapy
Petty, A. J., & Yang, Y. (2017) · Immunotherapy · doi:10.2217/imt-2016-0135 · Cited by 363
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J.-C., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 362
Rodriguez-Garcia, A., Lynn, R. C., Poussin, M., Eiva, M. A., Shaw, L. C., O’Connor, R. S., Minutolo, N. G., Casado-Medrano, V., Lopez, G., Matsuyama, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20893-2 · Cited by 341
Immune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339
Oaknin, A., Gilbert, L., Tinker, A. V., Brown, J., Mathews, C., Press, J., Sabatier, R., O’Malley, D. M., Samouelian, V., Boni, V., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003777 · Cited by 338
PD-1 and its ligands are important immune checkpoints in cancer
Dong, Y., Sun, Q., & Zhang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 334
Verma, V., Shrimali, R. K., Ahmad, S., Dai, W., Wang, H., Lu, S., Nandre, R., Gaur, P., Lopez, J., Sade-Feldman, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0441-y · Cited by 333 · cited 1×
“3).(84) Preclinical studies have shown that PD-1 inhibitors can inhibit the proliferation of cells and induce the programmed cell death (apoptosis) of various tumor cells.”
BackgroundRossi, J., Paczkowski, P., Shen, Y.-W., Morse, K., Flynn, B., Kaiser, A., Ng, C., Gallatin, K., Cain, T., Fan, R., et al. (2018) · Blood · doi:10.1182/blood-2018-01-828343 · Cited by 330
Liu, L., Bai, X., Wang, J., Tang, X.-R., Wu, D.-H., Du, S.-S., Du, X.-J., Zhang, Y.-W., Zhu, H.-B., Fang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0558 · Cited by 322
Moesta, A. K., Li, X.-Y., & Smyth, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0376-4 · Cited by 322
Herbst, R. S., Garon, E. B., Kim, D.-W., Cho, B. C., Gervais, R., Perez-Gracia, J. L., Han, J.-Y., Majem, M., Forster, M. D., Monnet, I., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.001 · Cited by 320
Paz-Ares, L. G., Ramalingam, S. S., Ciuleanu, T.-E., Lee, J.-S., Urban, L., Caro, R. B., Park, K., Sakai, H., Ohe, Y., Nishio, M., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.09.010 · Cited by 315
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
CD28-B7 interactions in T-cell activation
Allison, J. P. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90120-1 · Cited by 313
Sharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 312
SnapShot: Immune Checkpoint Inhibitors
Abril-Rodriguez, G., & Ribas, A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.010 · Cited by 309
Domingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308
NK cell-based immunotherapy for cancer
Fang, F., Xiao, W., & Tian, Z. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.009 · Cited by 306
Role of PD-1 in Regulating T-Cell Immunity
Jin, H.-T., Ahmed, R., & Okazaki, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_116 · Cited by 305
Herbst, R. S., Majem, M., Barlesi, F., Carcereny, E., Chu, Q., Monnet, I., Sanchez-Hernandez, A., Dakhil, S., Camidge, D. R., Winzer, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00227 · Cited by 304
CAR T cells: Continuation in a revolution of immunotherapy
Singh, A. K., & McGuirk, J. P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30823-x · Cited by 303
Immunogenicity of CAR T cells in cancer therapy
Wagner, D. L., Fritsche, E., Pulsipher, M. A., Ahmed, N., Hamieh, M., Hegde, M., Ruella, M., Savoldo, B., Shah, N. N., Turtle, C. J., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00476-2 · Cited by 303
Nogami, N., Barlesi, F., Socinski, M. A., Reck, M., Thomas, C. A., Cappuzzo, F., Mok, T. S. K., Finley, G., Aerts, J. G., Orlandi, F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.09.014 · Cited by 302
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130590 · Cited by 300
Singh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0813 · Cited by 295
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295
Cho, S.-F., Anderson, K. C., & Tai, Y.-T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01821 · Cited by 294
Monalizumab: inhibiting the novel immune checkpoint NKG2A
van Hall, T., André, P., Horowitz, A., Ruan, D. F., Borst, L., Zerbib, R., Narni-Mancinelli, E., van der Burg, S. H., & Vivier, E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0761-3 · Cited by 292
Wei, S. C., Meijers, W. C., Axelrod, M. L., Anang, N.-A. A. S., Screever, E. M., Wescott, E. C., Johnson, D. B., Whitley, E., Lehmann, L., Courand, P.-Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0856 · Cited by 290
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., & Brogdon, J. L. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2014.26 · Cited by 284
Watanabe, K., Luo, Y., Da, T., Guedan, S., Ruella, M., Scholler, J., Keith, B., Young, R. M., Engels, B., Sorsa, S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99573 · Cited by 283
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Kim, C. G., Kim, K. H., Pyo, K.-H., Xin, C.-F., Hong, M. H., Ahn, B.-C., Kim, Y., Choi, S. J., Yoon, H. I., Lee, J. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz123 · Cited by 282
Hu, Y., Zhou, Y., Zhang, M., Ge, W., Li, Y., Yang, L., Wei, G., Han, L., Wang, H., Yu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3863 · Cited by 280
Curran, K. J., Margossian, S. P., Kernan, N. A., Silverman, L. B., Williams, D. A., Shukla, N., Kobos, R., Forlenza, C. J., Steinherz, P., Prockop, S., et al. (2019) · Blood · doi:10.1182/blood.2019001641 · Cited by 279
Petrova, P. S., Viller, N. N., Wong, M., Pang, X., Lin, G. H. Y., Dodge, K., Chai, V., Chen, H., Lee, V., House, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1700 · Cited by 278
T cell senescence and CAR-T cell exhaustion in hematological malignancies
Kasakovski, D., Xu, L., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0629-x · Cited by 272
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
Park, A. K., Fong, Y., Kim, S.-I., Yang, J., Murad, J. P., Lu, J., Jeang, B., Chang, W.-C., Chen, N. G., Thomas, S. H., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz1863 · Cited by 271
Claus, C., Ferrara, C., Xu, W., Sam, J., Lang, S., Uhlenbrock, F., Albrecht, R., Herter, S., Schlenker, R., Hüsser, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5989 · Cited by 270
Segal, N. H., He, A. R., Doi, T., Levy, R., Bhatia, S., Pishvaian, M. J., Cesari, R., Chen, Y., Davis, C. B., Huang, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1922 · Cited by 267
Patterns of Response and Progression to Immunotherapy
Borcoman, E., Nandikolla, A., Long, G., Goel, S., & Le Tourneau, C. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200643 · Cited by 262
Sheih, A., Voillet, V., Hanafi, L.-A., DeBerg, H. A., Yajima, M., Hawkins, R., Gersuk, V., Riddell, S. R., Maloney, D. G., Wohlfahrt, M. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13880-1 · Cited by 262
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Fu, Y., Lin, Q., Zhang, Z., & Zhang, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.010 · Cited by 260
Rizzo, A., Ricci, A. D., & Brandi, G. (2021) · Cancers · doi:10.3390/cancers13030558 · Cited by 259
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250
IL-15 in the Combination Immunotherapy of Cancer
Waldmann, T. A., Dubois, S., Miljkovic, M. D., & Conlon, K. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00868 · Cited by 247
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y., & Wu, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.03.001 · Cited by 246
The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
Fu, T., He, Q., & Sharma, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1138 · Cited by 243 · cited 1×
“ICOS is expressed on the surface of activated T cells and regulates T-cell proliferation and function.(212) The activation of ICOS is dependent on its ligand ICOS-L, which is mainly expressed in B cells and APCs.”
BackgroundHan, G., Yang, G., Hao, D., Lu, Y., Thein, K., Simpson, B. S., Chen, J., Sun, R., Alhalabi, O., Wang, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25894-9 · Cited by 225
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
Cheema, T. A., Wakimoto, H., Fecci, P. E., Ning, J., Kuroda, T., Jeyaretna, D. S., Martuza, R. L., & Rabkin, S. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307935110 · Cited by 221
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Olson, D. J., Eroglu, Z., Brockstein, B., Poklepovic, A. S., Bajaj, M., Babu, S., Hallmeyer, S., Velasco, M., Lutzky, J., Higgs, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00079 · Cited by 221
Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids
Artegiani, B., van Voorthuijsen, L., Lindeboom, R. G. H., Seinstra, D., Heo, I., Tapia, P., López-Iglesias, C., Postrach, D., Dayton, T., Oka, R., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.04.017 · Cited by 218
Haanen, J. B. A. G., & Robert, C. (2015) · Progress in Tumor Research · doi:10.1159/000437178 · Cited by 208
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Becker, P. S. A., Suck, G., Nowakowska, P., Ullrich, E., Seifried, E., Bader, P., Tonn, T., & Seidl, C. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1792-y · Cited by 208
Cited by
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 390
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Metadata
- Authors
- Wang, D.-R., Wu, X.-L., & Sun, Y.-L.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2022-09-19
- Volume
- 7
- Issue
- 1
- Pages
- 331-331
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4296373959
- Cited by
- 501
- References
- 486
- FWCI
- 37.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.